- 作者：Marco H.M. Janssen ; M.Sc.&lowast ; ; marco.janssen@maastro.nl ; Michel C. Ö ; llers ; M.Sc. ; Ph.D.&lowast ; ; Ruud G.P.M. van Stiphout ; M.Sc.&lowast ; ; Robert G. Riedl ; M.D.&dagger ; ; Jø ; rgen van den Bogaard ; M.A.&lowast ; ; Jeroen Buijsen ; M.D.&lowast ; ; Philippe Lambin ; M.D. ; Ph.D.&lowast ; ; &Dagger ; ; Guido Lammering ; M.D. ; Ph.D.&lowast ; ; &Dagger ;
- 关键词：Locally advanced rectal cancer ; Chemoradiotherapy ; Sequential PET-CT imaging ; Pathological response prediction ; TRG
- 刊名：International Journal of Radiation Oncology*Biology*Physics
- 出版年：2012
- 出版时间：1 February 2012
- 年：2012
- 卷：82
- 期：2
- 页码：871-876
- 全文大小：378 K
Purpose
To develop a positron emission tomography (PET)-based response prediction model to differentiate pathological responders from nonresponders. The predictive strength of the model was validated in a second patient group, treated and imaged identical to the patients on which the predictive model was based.Methods and Materials
Fifty-one rectal cancer patients were prospectively included in this study. All patients underwent fluorodeoxyglucose (FDG) PET-computed tomography (CT) imaging both before the start of chemoradiotherapy (CRT) and after 2 weeks of treatment. Preoperative treatment with CRT was followed by a total mesorectal excision. From the resected specimen, the tumor regression grade (TRG) was scored according to the Mandard criteria. From one patient group (n = 30), the metabolic treatment response was correlated with the pathological treatment response, resulting in a receiver operating characteristic (ROC) curve based cutoff value for the reduction of maximum standardized uptake value (SUVmax) within the tumor to differentiate pathological responders (TRG 1?) from nonresponders (TRG 3?). The applicability of the selected cutoff value for new patients was validated in a second patient group (n = 21).
Results
When correlating the metabolic and pathological treatment response for the first patient group using ROC curve analysis (area under the curve = 0.98), a cutoff value of 48 % SUVmax reduction was selected to differentiate pathological responders from nonresponders (specificity of 100 % , sensitivity of 64 % ). Applying this cutoff value to the second patient group resulted in a specificity and sensitivity of, respectively, 93 % and 83 % , with only one of the pathological nonresponders being false positively predicted as pathological responding.
Conclusions
For rectal cancer, an accurate PET-based prediction of the pathological treatment response is feasible already after 2 weeks of CRT. The presented predictive model could be used to select patients to be considered for less invasive surgical interventions or even a ¡°wait and see?policy. Also, based on the predicted response, early modifications of the treatment protocol are possible, which might result in an improved clinical outcome.